CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its Toll-like Receptor-targeted drug discovery and development programs and a general corporate update at the following conferences:
